LV12539A - Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands - Google Patents

Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Info

Publication number
LV12539A
LV12539A LV000029A LV000029A LV12539A LV 12539 A LV12539 A LV 12539A LV 000029 A LV000029 A LV 000029A LV 000029 A LV000029 A LV 000029A LV 12539 A LV12539 A LV 12539A
Authority
LV
Latvia
Prior art keywords
substituted
napthyridine
carboxamides
oxo
agonists
Prior art date
Application number
LV000029A
Other versions
LV12539B (en
Inventor
Pamela Albaugh
Robert W Desimone
Gang Liu
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of LV12539A publication Critical patent/LV12539A/en
Publication of LV12539B publication Critical patent/LV12539B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention encompasses structures of Formula (I) or the pharmaceutically acceptable non-toxic salts thereof wherein: X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.
LVP-00-29A 1997-08-25 2000-03-16 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands LV12539B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (2)

Publication Number Publication Date
LV12539A true LV12539A (en) 2000-10-20
LV12539B LV12539B (en) 2001-01-20

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-00-29A LV12539B (en) 1997-08-25 2000-03-16 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Country Status (24)

Country Link
EP (1) EP1007526A1 (en)
JP (1) JP2001514181A (en)
KR (1) KR20010023313A (en)
CN (1) CN1268136A (en)
AP (1) AP2000001742A0 (en)
AU (1) AU753800B2 (en)
BG (1) BG104192A (en)
BR (1) BR9811362A (en)
CA (1) CA2301599C (en)
EG (1) EG21717A (en)
HU (1) HUP0003258A3 (en)
IL (1) IL134291A0 (en)
IS (1) IS5382A (en)
LV (1) LV12539B (en)
NO (1) NO20000822L (en)
NZ (1) NZ502548A (en)
OA (1) OA11293A (en)
PE (1) PE130999A1 (en)
PL (1) PL338783A1 (en)
SI (1) SI20270A (en)
SK (1) SK2162000A3 (en)
TW (1) TW574221B (en)
WO (1) WO1999010347A1 (en)
YU (1) YU10500A (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177177B1 (en) * 1999-05-06 2005-02-23 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
ATE430745T1 (en) 2000-10-12 2009-05-15 Merck & Co Inc AZA- AND POLYAZA NAPHTHALENYL CARBOXAMIDES AS INHIBITORS OF HIV INTEGRASE
AU1532802A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
US6841558B2 (en) 2000-10-12 2005-01-11 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
OA12554A (en) * 2001-03-01 2006-06-07 Pfizer Prod Inc Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders.
AR036256A1 (en) 2001-08-17 2004-08-25 Merck & Co Inc SODIUM SALT OF AN HIV INTEGRAS INHIBITOR, PROCESSES FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
WO2003077857A2 (en) 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
PL2074123T3 (en) * 2006-10-16 2013-04-30 Bionomics Ltd Novel anxiolytic compounds
JP2010510314A (en) * 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー Method for treating mental retardation, Down syndrome, fragile X syndrome and autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204813A1 (en) * 1972-05-08 1976-03-05 Yamanouchi Pharma Co Ltd PROCESS FOR THE PREPARATION OF AMPYLICIN DERIVATIVES
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD295360A5 (en) * 1987-07-03 1991-10-31 Akad Wissenschaften Process for the preparation of activated carboxylic acid esters
DD279887A1 (en) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun METHOD OF PREPARING D-ALPHA- (4 (1H) -1,5-NAPHTHYRIDONE-3-CARBOXAMIDO) -BENZYLPENICILLIN AND OTHER BETA LACTAMANTIBIOTICS
DD279875A1 (en) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun PROCESS FOR PREPARING ACTIVATED CARBONIC ACID ESTERS
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
BG104192A (en) 2001-05-31
AU9117398A (en) 1999-03-16
IL134291A0 (en) 2001-04-30
BR9811362A (en) 2000-08-22
SK2162000A3 (en) 2001-03-12
KR20010023313A (en) 2001-03-26
NO20000822D0 (en) 2000-02-18
YU10500A (en) 2002-10-18
CA2301599C (en) 2003-03-25
OA11293A (en) 2002-11-19
AP2000001742A0 (en) 2000-02-24
HUP0003258A3 (en) 2001-05-28
EG21717A (en) 2002-02-27
NO20000822L (en) 2000-04-13
HUP0003258A2 (en) 2001-03-28
EP1007526A1 (en) 2000-06-14
SI20270A (en) 2000-12-31
CA2301599A1 (en) 1999-03-04
WO1999010347A1 (en) 1999-03-04
CN1268136A (en) 2000-09-27
IS5382A (en) 2000-02-22
JP2001514181A (en) 2001-09-11
NZ502548A (en) 2002-06-28
LV12539B (en) 2001-01-20
TW574221B (en) 2004-02-01
PE130999A1 (en) 1999-12-16
PL338783A1 (en) 2000-11-20
AU753800B2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
LV12539A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
DK0555391T3 (en) Certain imidazoquinoxalins; a new class of GABA receptor ligands in the brain
CA2175204A1 (en) Certain Fused Pyrrolecarboxanilides; a New Class of GABA Brain Receptor Ligands
NZ330861A (en) Fused pyrrolecarboxamides and use as a new class of GABA brain receptor ligands
ATE280170T1 (en) CYCLOPENTA(B)(1,4) DIAZEPINO(6,7,1-HI)INDOLE AS 5HT2C ANTAGONISTS
PT1666462E (en) N-[1h-indol-5-yl]naphthalene-1-sulphonamide derivatives and related compounds as serotonin 5-ht6 receptor antagonists for the treatment of disorders of the central nervous system
NO20013001L (en) 2,3,4,4A-tetrahydro-1H-pyrazino (1,2-A) quinoxaline-5 (6H) one derivatives which are 5HT2C agonists
TW200510324A (en) 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
WO1999043661A3 (en) Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands
ATE277927T1 (en) ARYL AND HETEROARYL CONDENSED AMINOALKYL IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAA RECEPTORS
PE20020970A1 (en) IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
AU2321597A (en) Novel imidazo{1,5-c}quinazolines; a new class of gaba brain receptor ligands
ATE300539T1 (en) OXO-PYRIDOIMIDAZOLE-CARBOXAMIDE: GABA RECEPTOR LIGANDS IN THE BRAIN
KR920703594A (en) Imidazoquinoxaline compound, preparation method and use thereof
CA2249562A1 (en) Certain fused pyrrolecarboxamides as gaba brain receptor ligands
MXPA04008880A (en) New benzoindoline compounds, a process for their preparation and pharmaceutical compositions containing them.
MY107732A (en) Certain imidazoquinoxalines; a new class of gaba brain receptor ligands.
MX9709771A (en) Novel substituted aryl and cycloalkyl imidazolones; a new class of gaba brain receptor ligands.
AR007742A1 (en) FUSIONED PYROLCARBOXANILIDES; A NEW KIND OF LIGAND GABA BRAIN RECEPTORS.
FI921091A (en) Process for the preparation of therapeutically active 2-phenyl-substituted imidazo [1,5-a] quinoxaline-1,3 (2H, 5H) -dione derivatives